The pharmaceutical company AstraZeneca announced on Tuesday that its treatment Evusheld, based on a combination of long-acting antibodies against Covid-19, has been approved in the European Union for people over the age of 12, Agerpres reports.
The approval issued by the European Commission was based on the results of a phase 3 clinical trial aimed at treating Evusheld, representatives of the British-Swedish company said.
The results showed that a single dose of Evusheld provided clinically and statistically significant protection against the risk of worsening to severe Covid-19 disease and against the risk of death in non-hospitalized adults with mild to moderate symptoms for up to seven days.
Evusheld was already approved for sale in the European Union in March 2022, but the decision announced at the time by the European Medicines Agency (EMA) intended to use this cocktail of antibodies only as preventive pre-exposure therapy against Covid-19 for adults. and adolescents over 12 years of age whose immune systems were too weak to respond to vaccination. Evusheld is already available in most European countries.
The Evusheld therapeutic cocktail combines two types of synthetic antibodies (Tixagevimab and Cilgavimab) and is administered as two intramuscular injections. The treatment is considered effective against the Omicron variant of the new coronavirus.
Source: Hot News RU
James Springer is a renowned author and opinion writer, known for his bold and thought-provoking articles on a wide range of topics. He currently works as a writer at 247 news reel, where he uses his unique voice and sharp wit to offer fresh perspectives on current events. His articles are widely read and shared and has earned him a reputation as a talented and insightful writer.